AusME Biobank Biomarker Project

a close-up of a gloved hand holding a test tube containing a blood sample. The test tube is labeled with barcode for identification and tracking purposes.

The study aims to utilize the Australian ME/CFS biobank for metabolomics analyses and other assays to identify potential biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, contributing to a comprehensive dataset for large-scale analysis.

The Life Improvement Trial (LIFT)

Headshots of Jonas Bergquist and David Systrom alongside the text “The LIFT.”

The Life Improvement Trial (LIFT) aims to investigate two drugs, separately and in combination, Pyridostigmine (commonly known as Mestinon) and Low-Dose Naltrexone (LDN), for efficacy and to research the difference between responders and non-responders.

Temporally Resolved Omics Tracking of ME/CFS

Woman researcher doing a blood test

This study seeks to understand the biological mechanisms driving the symptomatology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) using metabolomic and lipidomic high-throughput analysis and high-frequency blood sampling over a 6.5 to 7.5 hour period conducted at two separate sites (Melbourne and Uppsala).

iCPET Omics Studies of ME/CFS

This Harvard study evaluates the different explanations of heart preload failure in ME/CFS patients to determine which is active in many, if not all, ME/CFS patients. The Computation Center is now seeking to better understand the causes of ME/CFS (PLF, the high flow type) as well as to identify potential drug targets for future therapies.

OMF Data Center

The purpose of the OMF Data Center is to house raw data and processed results, which is shared with our research network through the web-based data portal.

COVID to Long COVID to ME/CFS​

OMF secured a $1 million grant to launch the first year of an international, multi-year study across the six OMF supported Collaborative Research Centers (CRC). The aim of this study is to examine Long COVID transitioning to ME/CFS.